A type 1 diabetic mystery is why do some Type 1s get complications and others seem to never get them? A massive Japanese study of Type 1 diabetics found that those with fulminant diabetes developed complications much faster and more severely than those with non-fulminant diabetes.

The difference between fulminant and non-fulminant is the speed and intensity at which the disease develops. Fulminant Type 1 diabetes typically develops suddenly with near total loss of beta cell function. This type of diabetes is confirmed with testing c-peptide levels. Non-fulminant type 1 diabetes has residual c-peptide levels that eventually taper to undetectable. Sometimes this is seen through many years of the Honeymoon Period.

This study may be the antithesis of conventional wisdom for preventing complications. Staking all hopes on blood sugar control is heavily optimistic. Yes controlling blood sugar does lessen the workload for existing beta cells, and thus extends the lifespan of each beta cell. Research suggests that c-peptide offers protection to beta cells, both from apoptosis (cell death) and encourages new cell growth. This new cell growth applies to beta cells and other cells of the body that endure long-term Type 1 diabetes complications.

Diabetics are instructed that maintaining normal blood sugars is the Holy Grail of preventing long-term complications. Yes and no. The truth is controlling your blood sugar will not allow complications of Type 1 diabetes to develop as quickly, presuming you still had some level of beta cell function upon diagnosis (i.e., c-peptide). That doesn't sound like a reward as much as it does a delayed punishment. I'd like c-peptide with my insulin, please. It's off the à la carte menu? That's fine - serve it up! I want to thank Klausen for bringing this study to my attention.

I contacted Novo Nordisk back in March to tell them about the remarkable effects C-peptide had on reversing complications of Type 1 diabetes. I asked if they would bring the drug to market. A mass of excitement overwhelmed me when I learned about C-peptide missing from insulin all these years. The response from Novo? No thanks, it's not one of our targets. Targets, eh?

C-peptide is a byproduct of the production of insulin. In Type 1 diabetics, the level of C-peptide eventually becomes undetectable due to the body not making any insulin of its own. Long-term complications of diabetes frequently develop despite insulin therapy and optimal blood glucose control. C-peptide could quite possibly be the missing link in perfect diabetes control. I sent the following document to Novo Nordisk and asked them to make C-peptide available to reverse and ameliorate renal and nerve dysfunction for Type 1 diabetics. Read the document and see for yourself the eye-popping beneficial results C-peptide offers Type 1 diabetics. I received it directly from Dr. Wahren, lead researcher for C-peptide.

After 5 months consideration, Novo called me back. They said C-peptide is not a target for their company. I understand and now Levemir is not a target in my diabetes control, either. For all the Type 1 diabetics out there controlling your sugars with insulin not really made with you in mind -- do you understand why Novo does not wish to develop this critically important treatment? I guess insulin is good enough, right? Wrong. It's a tough job but somebody's got to do it. Just not Novo. When you are in the business of diabusiness -- no thank you says so much about what could potentially hurt your business.

Remember the A-Game suggestions I dangled for Eli Lilly to tap for performance enhancement? Well here it comes. I called Eli Lilly headquarters to speak with the Chairman and CEO, Mr. Sidney Taurel but I was directed to their idea submission form (which consequently didn't work). Oh boy, Sid. I'm a little disappointed. So here goes - my idea is going free for all when you could've had it, first. Let's call this new and improved product Beta Juice. It delivers the essential functions of a fully operational beta cell. It produces: insulin, amylin and c-peptide. Here's why insulin should always come equipped with the other two...

Insulin brings sugar to the cells to keep our energy levels sufficient for life, homeostasis and (if we're lucky) some energy for the gym. Amylin is a controlling agent for appetite, gastric emptying and tells the liver to dispatch glucose. It is also shown to have an impact on lipolysis --- the metabolism of stored fat. Until recently C-peptide was nothing more than a number used to decipher if you were a type 1 or a type 2 diabetic. However, recent scientific studies have shown C-peptide protects small vessels from the complications associated with diabetes. The Reuters Health article is titled C-Peptide Replacement Improves Early Diabetic Neuropathy.

The American Diabetes Association promotes the ABC's of Diabetes Care in an effort to educate diabetics on controlling their disease. The ABC's of diabetes care refer to a patient's Hemoglobin A1c, blood pressure, and cholesterol. A diabetic must maintain a hemoglobin A1c less than 7%, their blood pressure must remain below 130/80 and their good and bad cholesterol must be kept in range. The ABCs of Diabetes Care were established in order to reduces the chances of developing diabetic complications like neuropathy (nerve damage), nephropathy (kidney damage) and retinopathy (eye damage).

Here comes the perfect Insulin (code name Beta Juice) -a laboratory engineered balance of insulin, amylin, and C-peptide. Insulin to balance the blood sugar level, amylin to regulate fat and cholesterol levels and C-peptide to control the damage inflicted upon the micro vessels throughout the body. This is a GREAT IDEA!! Not just because it is MY idea, but because this is a huge opportunity to mitigate the complications that insulin by itself can impose, without the checks and balances of the other beta cell hormones. What do you say, Eli Lilly? You're halfway there!! You've already partnered with Amylin Pharmaceuticals. They have one third of this patent pie. Now hop on the horn and join forces with the C-peptide patent holder and ride your stock price to the moon. The diabetic girl has spoken. I know you care, Eli Lilly. Now put your money where your mouth is and make this new and improved insulin a light at the end of the diabetes tunnel.

A study from U.S. researchers has found that daily supplementation with a cinnamon extract may boost the body's antioxidants, which can lessen the complications associated with metabolic syndrome. Metabolic syndrome is characterized by obesity -- especially around the midsection -- hypertension and reduced metabolism of both glucose and insulin. The syndrome is associated with an increased risk in the development of type 2 diabetes and cardiovascular disease.

The study recruited 24 participants with impaired fasting glucose levels for a double-blind, placebo-controlled study. The patients were split into two randomly assigned groups: the first received a daily dose of 500 mg of cinnamon extract and the second received a placebo. After 12 weeks, the researchers found that in the cinnamon extract group, antioxidant levels were significantly increased compared to the placebo group. Plasma levels of a reactive compound related to oxidative stress were also lower in the cinnamon group, but remained unchanged in the placebo patients. Oxidative stress is responsible for many of the microvascular changed responsible for diabetes complications: blindness, numbness, kidney damage, and amputations.

Beyond the resounding proof of cinnamon being helpful in diabetes management, other health-related benefits include: improved digestion, toning of tissues, relief from congestion, muscle and joint pain relief, relief from menstrual cramping, thinning of the blood and better circulation, relief from arthritis pain, prevention of urinary tract infections, prevention of tooth decay, and killing of harmful bacteria. I think a sprinkle of cinnamon is worth the pound of prevention this little spice is punching. How much is 500 mg of cinnamon anyway?

Even though kids with Type 2 diabetes typically develop the disease at an older age than Type 1 kids, they are more likely to suffer serious complications such as high blood pressure and signs of kidney damage. That is, a youngster who is diagnosed with Type 2 diabetes at age fourteen is at a greater risk for complications than a friend of the same age with Type 1 diabetes who was diagnosed at age five and has been living with the disease all that time. This is according to new research carried out by staff at the Children's Hospital at Westmead, Sydney in Australia.

Parents and physicians need to take note of this new information. The implication of the findings is that children need to be screened for such complications immediately upon diagnosis for Type 2. In addition, the researchers suggest it would make sense to screen kids who are at risk for Type 2 diabetes, just to be on the safe side. The results of this study have been published in Diabetes Care (June 2006).